Report
Martial Descoutures

INVEST SECURITIES - Celyad : Consolidation de la trésorerie en amont de 2019 - ACHAT, OC 32€ vs 36,2€

Nous actualisons notre modèle en intégrant le placement privé de 40,1m€ réalisé en fin de semaine dernière. Cette opération vient renforcer la trésorerie du groupe qui présentait un niveau de 25m€ fin du T1 pour une consommation estimée autour des 9m€ par trimestre. Alors que les données préliminaires de l'essai THINK soulevaient des interrogations, le premier retour de LINK et SHRINK semble rassurant. Nous maintenons notre recommandation à ACHAT avec un ajustement de notre OC à 32€ vs 36,2€ préc.
Underlying
Celyad Oncology

Celyad is engaged in engineered cell therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology. Co. provides C-CATHez, an injection catheter that delivers bio therapeutic agents into the myocardium. Co.'s main product is C-Cure, which is in Phase III clinical trials for the treatment of chronic heart failure secondary to ischemic cardiomyopathy. Co.'s drug product candidates are autologous cell therapy treatments. In autologous procedures, a patient's cells are harvested, selected, reprogrammed and expanded, and then infused back into the same patient.

Provider
Invest Securities
Invest Securities

Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.

Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Invest Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch